改良多西他赛联合顺铂、氟尿嘧啶与奥沙利铂联合卡培他滨治疗晚期胃癌疗效分析  

Efficacy Analysis of Modified Docetaxel Plus Cisplatin,Fluorouracil and Oxaliplatin Plus Capecitabine in Treatment of Advanced Gastric Cancer

作　　者：樊春梅[1] 邵长江 Fan Chun-mei;Shao Chang-jiang(Donghai County People's Hospital in Lianyungang,Lianyungang 222300,Jiangsu Province,China)

机构地区：[1]江苏省连云港市东海县人民医院,江苏连云港222300

出　　处：《中国社区医师》2022年第18期22-24,27,共4页Chinese Community Doctors

摘　　要：目的:观察改良多西他赛联合顺铂及氟尿嘧啶(DCF)方案与奥沙利铂联合卡培他滨(XELOX)方案治疗老年晚期胃癌的临床效果与安全性。方法:回顾性分析2018年1月-2020年12月东海县人民医院收治的晚期胃癌老年患者共80例作为研究对象,根据治疗方法不同将其分为观察组与对照组,各40例。对照组应用改良DCF法治疗,观察组应用XELOX方案治疗。对两组患者不同方法治疗后客观有效率(RR)、控制率(DCR)及不良反应发生情况进行比较。结果:对照组应用改良DCF方案后与观察组应用XELOX治疗在RR与DCR方面比较,差异无统计学意义(P>0.05)。对照组中位无进展生存期(mPFS)与总生存期(mOS)较观察组显著延长,两组患者mPFS比较,差异有统计学意义(14.2个月vs.5.8个月,P=0.002),两组患者mOS比较,差异无统计学意义(20.8个月vs.12.0个月,P=0.107)。对照组Ⅲ~Ⅳ级胃肠道反应发生较观察组更高,观察组Ⅲ~Ⅳ级神经毒性及手足综合征发生率显著高于对照组,差异有统计学意义(P<0.05)。结论:改良DCF方案及XELOX方案均是治疗晚期胃癌的一线方案,疗效相近,改良DCF方案PFS延长,Ⅲ-Ⅳ级神经毒性及手足综合征发生率更低。Objective:To observe the clinical effect and safety of modified docetaxel,cisplatin and fluorouracil(DCF)regimen and oxaliplatin plus capecitabine(XELOX)regimen in the treatment of elderly patients with advanced gastric cancer.Methods:A total of 80 elderly patients with advanced gastric cancer who were admitted to Donghai County People's Hospital from January 2018 to December 2020 were retrospectively analyzed as the study subjects.According to different treatment methods,they were divided into an observation group and a control group with 40 cases in each group.The control group was treated with modified DCF method,and the observation group was treated with XELOX regimen.The objective response rate(RR),disease control rate(DCR)and adverse reactions were compared between the two groups of patients after different methods of treatment.Results:There was no significant difference in RR and DCR between the control group after the modified DCF regimen and the observation group after XELOX treatment(P>0.05).The median progression-free survival(mPFS)and overall survival(mOS)in the control group were significantly longer than those in the observation group.There was a statistically significant difference in mPFS between the two groups(14.2 months vs.5.8 months,P=0.002).There was no significant difference in mOS between the two groups(20.8 months vs.12.0 months,P=0.107).The incidence of gradeⅢ~Ⅳgastrointestinal reactions in the control group was higher than that in the observation group,and the incidence of gradeⅢ~Ⅳneurotoxicity and hand-foot syndrome in the observation group was significantly higher than that in the control group,and the difference was statistically significant(P<0.05).Conclusion:Modified DCF regimen and XELOX regimen are both the first-line regimens for the treatment of advanced gastric cancer,with similar efficacy.Modified DCF regimen prolongs PFS,and has a lower incidence of grade III-IV neurotoxicity and hand-foot syndrome.

关 键 词：改良多西他赛联合顺铂及氟尿嘧啶方案 奥沙利铂联合卡培他滨方案 胃癌晚期 老年 安全性 

分 类 号：R735.2[医药卫生—肿瘤]